Although there have been five years since its approval in the United States for the management of Autism Spectrum Disorders (ASD), in Colombia the use of aripiprazole for this indication remains off-label. In this context, we have proposed the implementation of a systematic literature review to determine the effectiveness and safety of this therapeutic strategy in the light of available evidence in the management of children and adolescents with ASD.
